Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB06 Golimumab
D04358 Golimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunosuppressants
Tumor Necrosis Factor (TNF) Blockers
Golimumab
D04358 Golimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D04358 Golimumab (USAN/INN); Golimumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
D04358 Golimumab
Drug classes [BR:br08332]
Immunological agent
DG01936 TNF inhibitor
D04358 Golimumab
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D04358 Golimumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D04358 Golimumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04358
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04358
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04358
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04358
